eGFR slope change in IgAN patients with active renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR slope change in IgAN patients with active renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR slope change in IgAN patients with active renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR slope change in IgAN patients with active renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR slope change in IgAN patients with active renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR slope change in IgAN patients with active renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR slope change in IgAN patients with chronic renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR slope change in IgAN patients with chronic renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR slope change in IgAN patients with chronic renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR slope change in IgAN patients with chronic renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR slope change in IgAN patients with chronic renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR slope change in IgAN patients with chronic renal lesions
eGFR slope change calculated as the mean of the individual slopes obtained from individual linear regression of eGFR over time;
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with active renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
eGFR decline >40% in IgAN patients with chronic renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with active renal lesions
composite endpoint: eGFR decline > 40%, ESKD and death due to kidney disease in IgAN patients with chronic renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with chronic rena lesions
composite endpoint: eGFR decline > 40%, ESKD and death due to kidney disease in IgAN patients with chronic renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with chronic rena lesions
composite endpoint: eGFR decline > 40%, ESKD and death due to kidney disease. in IgAN patients with chronic renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with chronic renal lesions
composite endpoint: eGFR decline > 40%, ESKD and death due to kidney disease. in IgAN patients with chronic renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with chronic renal lesions
composite endpoint: eGFR decline > 40%, ESKD and death due to kidney disease. in IgAN patients with chronic renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with chronic renal lesions
composite endpoint: eGFR decline > 40%, ESKD and death due to kidney disease. in IgAN patients with chronic renal lesions
composite endpoint: eGFR decline > 40%, ESKD (defined as long-term eGFR < 15 ml/min/1.73m2 for more than 3 months or need of maintenance dialysis or kidney transplantation) and death due to kidney disease in IgAN patients with chronic renal lesions
proteinuria reduction (geometric mean of 30% within 6 months)
proteinuria reduction in IgAN patients with chronic renal lesions
proteinuria reduction (geometric mean of 30% within 6 months)
proteinuria reduction in IgAN patients with chronic renal lesions
proteinuria reduction (geometric mean of 30% within 6 months)
proteinuria reduction in IgAN patients with chronic renal lesions
proteinuria reduction (geometric mean of 30% within 6 months)
proteinuria reduction in IgAN patients with chronic renal lesions
proteinuria reduction (geometric mean of 30% within 6 months)
proteinuria reduction in IgAN patients with chronic renal lesions
proteinuria reduction (geometric mean of 30% within 6 months)
proteinuria reduction in IgAN patients with chronic renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with active renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with active renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with active renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with active renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with active renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with active renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with active renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with active renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with chronic renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with chronic renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with chronic renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with chronic renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with chronic renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement in IgAN patients with chronic renal lesions
time-averaged proteinuria (TA-P) calculated as the weighted mean of all post-randomization measurement, with weights representing the time elapsed since the previous measurement